GILD vs REGN
GILD and REGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $181.41B | — |
| P/E (TTM) | 21.6 | 19.1 |
| P/B | 15.34 | — |
| P/S | 6.2x | — |
| Dividend yield | 2.21% | — |
| Revenue | $30.46B(TTM) | $15.53B(TTM) |
| Revenue growth (YoY) | 2.4% | 1.0% |
| Net income | -$3.24B(TTM) | $4.33B(TTM) |
| Earnings growth (YoY) | 1672.9% | 2.1% |
| EPS, diluted | $-2.65(TTM) | $40.41(TTM) |
| EBIT margin | 34.0% | 24.9% |
| ROE | 71.9% | 14.2% |
| ROIC | 26.7% | 9.4% |
| 1y total return | +32.9% | +35.0% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: GILD frente a REGN
| Métrica | GILD | REGN |
|---|---|---|
| Valor final | $25.5K | $21.4K |
| Retorno total | +154.7% | +113.7% |
| CAGR | +9.5% | +7.6% |
| Volatilidad | 25.6% | 32.1% |
| Sharpe | 0.32 | 0.26 |
| Sortino | 0.48 | 0.38 |
| Caída máxima | -30.5% | -59.7% |
Basado en 2600 días de negociación comunes, 2016-05-12 → 2026-09-15 · tasa libre de riesgo 4.11% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)